Highest-materiality recent filing
908 Devices issues 3.2M shares to satisfy RedWave earnout; revenue threshold of $37M met
Issued 3,213,583 shares of common stock as earnout consideration under the RedWave acquisition.
908 Devices shareholders elect directors, ratify auditor, approve exec comp at 2026 annual meeting
Board elected Class III directors Keith Crandell (23.99M for), Christopher Brown (24.12M), Kevin Hrusovsky (21.16M).
908 Devices Q1 rev +14% to $13.4M, raises FY26 outlook; buys NIRLAB for $15M
Q1 revenue $13.4M (+14% YoY); recurring revenue $4.0M (30% of total); gross margin 51%, adj. 57%.
908 Devices Q4 rev $17.4M (+21% YoY); positive adj. EBITDA; FY2026 guide $64.5-67.5M
Q4 revenue $17.4M (up 21% YoY); full-year revenue $56.2M (up 18% YoY).
908 Devices Q4 revenue $17.2M (+20% YoY); FY2025 ~$56M (+17%), positive Adj. EBITDA in Q4
Q4 2025 revenue ~$17.2M versus $14.3M in Q4 2024, growth of ~20%.
Q3 revenue of $14.0M, down 4% YoY; first nine months revenue up 16% to $38.8M; installed base grew 27% YoY to 3,512 devices.
908 Devices Q2 revenue $13.0M (+14% YoY); raises 2025 revenue outlook to $54-56M
Revenue from continuing ops $13.0M (+14% YoY); recurring revenue $4.7M (+28%, 36% of total).
908 Devices appoints Dr. Brandi Vann to board; Jeff George resigns
Jeff George resigned from Board effective July 31, 2025; departure follows sale of bioprocessing portfolio.
Board changes: Eisenberg resigns, co-founder Brown appointed director
Marcia Eisenberg resigned from board and compensation committee effective June 12, 2025.
908 Devices stockholders re-elect three Class II directors and ratify auditor at annual meeting
Directors Kevin Knopp, Tony Hunt, and Mark Spoto re-elected with 17.1M–17.3M votes for each; broker non-votes of 6.5M.
908 Devices Q1 revenue up 59% to $11.8M; reiterates FY25 outlook of $53-55M
Total revenue from continuing ops $11.8M (+59% YoY); handheld product & service revenue $11.0M (+86%).
Sold desktop portfolio (Maverick, Rebel, Maven, Trace C2, ZipChip) to Repligen for ~$66M net upfront cash after transaction costs.
908 Devices sells desktop bioprocessing PAT portfolio to Repligen for $70M cash
Purchase price $70M in cash, subject to customary working capital adjustment and escrow for indemnification.
908 Devices Q4 revenue up 31% YoY; divests desktop business to Repligen for $70M
Q4 revenue $18.8M (+31% YoY); full year $59.6M (+19% YoY); recurring revenue 39% of total.
Revenue increased 17% year over year to $16.8 million, driven by handheld product sales.
908 Devices posts updated investor presentation on website
Updated Investor Presentation posted to ir.908devices.com on August 30, 2024.
Q2 revenue up 16% to $14M, net loss widens to $12.5M; reiterates FY24 guidance $63-65M
Revenue $14.0M (+16% YoY); handheld devices up 26% to $11.1M, desktop down 9% to $2.9M.
908 Devices files RedWave financials; acquired firm had $13.8M revenue, $2.1M net income in 2023
Acquisition of RedWave (CAM2 Technologies) closed April 29, 2024; now a wholly-owned subsidiary of 908 Devices.
908 Devices appoints former DEA Administrator Michele Leonhart to Board of Directors
Michele Leonhart joined Board as Class I director on June 25, 2024; term expires at 2027 annual meeting.
908 Devices shareholders elect two Class I directors, ratify PwC as auditor
Fenel M. Eloi elected with 18,885,971 For, 4,548,553 Withheld, 6,047,784 broker non-votes.
908 Devices acquires RedWave Technology for $53.5M in cash and stock; expands forensics portfolio
Initial consideration: $45M cash + 1.5M shares ($8.5M); total $53.5M. Up to 4M earnout shares (≈$22.7M) if revenue hits $37M-$45M over 2 years.
908 Devices Q1 revenue $10.0M (+5% YoY); acquires RedWave for $45M; FY24 guidance $63-65M
Revenue $10.0M (+5% YoY); handheld devices $7.4M (+20%), desktop $2.6M (-18%).
Q4 revenue $14.4M (+23% YoY); net loss $7.4M; FY 2024 guidance $52-54M
Q4 revenue $14.4M, up 23% YoY; handheld revenue +57% in Q4.
908 Devices Q3 revenue $14.3M (-9% YoY), net loss $7.1M; narrows 2023 outlook
Revenue $14.3M in Q3 2023 vs $15.7M in Q3 2022; handheld $11.7M, desktop $2.5M, recurring $3.6M.
908 Devices Q2 revenue up 9% to $12.1M; raises FY2023 guidance low end
Q2 revenue $12.1M (+9% YoY); handheld rev $8.8M (+27%); recurring rev $4.0M (+39%).
908 Devices stockholder meeting re-elects directors, ratifies auditor
Class III directors Crandell, Eisenberg, Hrusovsky re-elected; Crandell received 18.5M for, 7.7M withheld.
908 Devices Q1 revenue up 14% to $9.5M; net loss widens to $12.5M; reiterates FY23 outlook
Revenue $9.5M (+14% YoY); recurring revenue $4.2M (+67%); handheld up 38%, desktop down 13%.
908 Devices reports Q4 2022 revenue down 27% YoY to $11.6M; guides FY2023 rev $48-52M
FY2022 revenue $46.9M (+11% YoY); recurring revenue up 101% to $15.7M, representing 1/3 of total.
908 Devices Q3 revenue up 26% to $15.8M, guides FY2022 revenue $46M-$49M
Revenue $15.8M (+26% YoY); gross margin 59% vs 54%.
908 Devices replaces $25M SVB credit line with $35M Silicon Valley Bank facility, maturing Nov 2025
New $35M revolving credit line with Silicon Valley Bank; replaces prior $25M Signature Bank facility.
908 Devices reports Q2 revenue $11.1M (+34% YoY), reiterates FY22 guidance; acquires TRACE Analytics
Q2 revenue $11.1M, up 34% YoY; gross margin 60% vs 53% prior year.
908 Devices reports 2022 annual meeting vote results; all directors elected, auditor ratified
All three Class II director nominees elected (Knopp: 20.5M for, 4.0M withheld; Hunt: 24.1M for, 0.4M withheld; Spoto: 16.3M for, 8.2M withheld).
908 Devices Q1 revenue up 50% to $8.3M; reiterates FY22 guidance $52-55M
Revenue $8.3M (+50% YoY); net loss $9.4M ($0.30/share) vs $6.1M ($0.22) last year.
Director Nicolas Barthelemy not to stand for re-election at June 2022 annual meeting
Nicolas Barthelemy will not stand for re-election to board at June 2022 Annual Meeting; serves until then as director and Compensation Committee chair.
908 Devices Q4 rev $15.8M (+177% YoY); net loss $3.5M; FY22 guide $52-55M
Full-year 2021 revenue $42.2M (+57% YoY); net loss $22.2M ($0.79 loss per share).
908 Devices appoints Repligen CEO Tony J. Hunt to Board, effective March 2, 2022
Tony J. Hunt, President and CEO of Repligen (RGEN), appointed to Board expanding from 8 to 9 directors.
908 Devices pre-announces Q4 revenue ≥$15.1M (+165% YoY); FY21 ≥$41.5M (+54% YoY)
Preliminary Q4 2021 revenue at least $15.1M, up from $5.7M in Q4 2020 (+165%).
908 Devices Q3 revenue $12.5M (+107% YoY), net loss $5.2M; narrows FY guidance to $41-43M
Q3 revenue $12.5M, up 52% sequentially and 107% YoY; net loss $5.2M ($0.19 loss per share).
908 Devices Q2 revenue $8.3M; raises 2021 revenue outlook to $40-43M (49-60% YoY growth)
Revenue $8.3M, up 49% from Q1 2021 and down 26% from $11.1M in Q2 2020 on a one-time prior-year shipment.
On June 13, 2025, Christopher D. Brown was appointed to the Board to fill the vacancy created following Ms. Eisenberg’s resignation.
On June 12, 2025, Marcia Eisenberg resigned from the Board of Directors (the “Board”) of 908 Devices Inc. (the “Company”) and the Compensation Committee of the Board. Her resignation was effective on June 12, 2025 at 5:00 p.m. Eastern Time.
On June 25, 2024, Michele M. Leonhart was appointed to the Board of Directors (the “Board”) of 908 Devices Inc.
On April 11, 2022, Nicolas Barthelemy advised the Board of Directors (the “Board”) of 908 Devices Inc. (the “Company”) of his decision not to stand for re-election as a member of the Board at the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”) to be held in June 2022.
On March 2, 2022, Tony J. Hunt was appointed to the Board of Directors
Max materiality 0.85 · Median 0.65 · Most common event earnings